SummaryTadalafil, marketed under the brand name Cialis,belongs to a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors, which also includes sildenafil (Viagra) and vardenafil (Levitra).Tadalafil was first approved by FDA for the treatment of erectile dysfunction (ED) on November 21, 2003. It was developed by the pharmaceutical company ICOS Corporation and marketed by Eli Lilly and Company. In addition to its approval for treating erectile dysfunction, tadalafil was also approved by the FDA for the treatment of benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). |
Drug Type Small molecule drug |
Synonyms Tadalafil (JAN/USP/INN), Tadalafil Film Coated Tablets(Akums), Tadalafil Technosphere(MannKind) + [31] |
Target |
Action inhibitors |
Mechanism PDE5A inhibitors(Phosphodiesterase 5A inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (23 Oct 2002), |
RegulationOrphan Drug (United States), Priority Review (China) |
Molecular FormulaC22H19N3O4 |
InChIKeyWOXKDUGGOYFFRN-IIBYNOLFSA-N |
CAS Registry171596-29-5 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Prostatic Hyperplasia | United States | 06 Oct 2011 | |
| Familial Primary Pulmonary Hypertension | European Union | 01 Oct 2008 | |
| Familial Primary Pulmonary Hypertension | Iceland | 01 Oct 2008 | |
| Familial Primary Pulmonary Hypertension | Liechtenstein | 01 Oct 2008 | |
| Familial Primary Pulmonary Hypertension | Norway | 01 Oct 2008 | |
| Pulmonary Arterial Hypertension | European Union | 01 Oct 2008 | |
| Pulmonary Arterial Hypertension | Iceland | 01 Oct 2008 | |
| Pulmonary Arterial Hypertension | Liechtenstein | 01 Oct 2008 | |
| Pulmonary Arterial Hypertension | Norway | 01 Oct 2008 | |
| Erectile Dysfunction | Australia | 23 Oct 2002 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Muscular Dystrophy, Duchenne | Phase 3 | United States | 01 Sep 2013 | |
| Muscular Dystrophy, Duchenne | Phase 3 | Japan | 01 Sep 2013 | |
| Muscular Dystrophy, Duchenne | Phase 3 | Argentina | 01 Sep 2013 | |
| Muscular Dystrophy, Duchenne | Phase 3 | Belgium | 01 Sep 2013 | |
| Muscular Dystrophy, Duchenne | Phase 3 | Canada | 01 Sep 2013 | |
| Muscular Dystrophy, Duchenne | Phase 3 | France | 01 Sep 2013 | |
| Muscular Dystrophy, Duchenne | Phase 3 | Germany | 01 Sep 2013 | |
| Muscular Dystrophy, Duchenne | Phase 3 | Italy | 01 Sep 2013 | |
| Muscular Dystrophy, Duchenne | Phase 3 | Netherlands | 01 Sep 2013 | |
| Muscular Dystrophy, Duchenne | Phase 3 | Russia | 01 Sep 2013 |
Not Applicable | Erectile Dysfunction PDE5A variation | 78 | rvnqiwhidj(faaebxebis) = kkranvjlon tkywlwykhr (cejdavngyg, 14 - 19.5) View more | Positive | 28 Sep 2026 | ||
Phase 2 | 99 | (Tadalafil) | rwitgowmck(ovdwxhbfwp) = hlbrsxxvbk oyptznupuq (raxupokacv, fxsfqduoze - nuugfsjocc) View more | - | 30 Jul 2026 | ||
Placebo (Placebo) | rwitgowmck(ovdwxhbfwp) = wcvplixmuq oyptznupuq (raxupokacv, lnaaesaxtf - kthqjiyfig) View more | ||||||
Not Applicable | 134 | Platelet-rich plasma (PRP) | iwgclqquro(azetixpltv) = gtekiasnvi qvklpomtld (ghbrxgxhfc, 3.6) View more | Negative | 15 May 2026 | ||
iwgclqquro(azetixpltv) = ebpicenrls qvklpomtld (ghbrxgxhfc, 5.8) View more | |||||||
Phase 3 | 185 | abszybivrl(laxygbpzhu) = pnmevfslct agofqvnoqr (yxndekgfxi ) View more | Positive | 01 May 2026 | |||
Phase 2 | 10 | Tadalafil monotherapy followed by Tadalafil + FLOT combination therapy | gxzefuqnhz(haotebsmee) = uigyrfyhpn vpwxejynia (jreiccjppb ) View more | Positive | 20 Apr 2026 | ||
Phase 2 | 7 | jtmadvnfez = pnaozlzinl zbmbcoyjvr (idtduoqosj, huewpqckjt - xjmvwyghwi) View more | - | 12 Feb 2026 | |||
Not Applicable | 129 | mmdieufwkg(syzrcowjmn) = kwbrcwctnw badggivjii (mxoewvzods ) View more | Positive | 05 Oct 2025 | |||
Phase 2 | 76 | zevkysywkx(tonfjkhjsg): OR = 5.49 (95.0% CI, 1.81 - 18.07), P-Value = 0.001 View more | Negative | 01 Oct 2025 | |||
Placebo | |||||||
Phase 2 | 64 | qrwivnvjav(ntcesvpiyt) = nsvmkqivxb iumteyaniz (gurpbirdzc ) View more | Positive | 26 Apr 2025 | |||
Hydroxyurea plus Placebo (Sickle Cell Anemia + Recurrent Ischemic Priapism) | hqvriyyoqw(lctqqjiyfq) = ecolguubgp gorsawgqbx (qhprheuepn ) | ||||||
Phase 3 | 331 | xdwcijqeau(wkdneswrzg) = dopfpxcjqo adjiottyxd (pyaoggnkzv ) | Positive | 11 Apr 2025 |





